- Protocol on Establishing a National Disease
- Registry Swiss Pediatric Inflammatory
- Brain Disease Registry
- 4 Swiss Pediatric Inflammatory Brain Disease Registry
- 6 Lorena Freya Hulliger¹, Anne Tscherter¹, Claudia Kühni¹, Sandra Bigi^{1,2},
- 7 Institute of Social and preventive medicine, University of Bern, Bern, Bern, Switzerland
- 8 ²Department of Neuropediatrics, Lucerne cantonal hospital, Children's hospital, Lucerne, Lucerne,
- 9 Switzerland

Metadata

11 Funding

- 12 This project is funded by the following organizations: Swiss Multiple Sclerosis Society, Roche Pharma
- 13 (Switzerland) Ltd, Novartis Pharma Schweiz AG, and Sanofi-Aventis (Schweiz). The funders had no role in
- the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- 15 Competing interests
- None of the authors have any potentially competing interest to declare.
- 17 Data availability
- 18 This manuscript is purely technical and does not include any data beyond number of identified potential
- 19 study participants and number of signed informed consent forms.

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

Abstract Background Pediatric-onset inflammatory brain diseases are a group of potentially life-threatening central nervous system disorders. Overall, pediatric-onset inflammatory brain diseases are rare and therefore difficult to study. Patient registries are well suited to study the natural history of (rare) diseases and have markedly advanced the knowledge on pediatric-onset inflammatory brain diseases in other countries. Following their example, we established a national pediatric-onset inflammatory brain disease registry in Switzerland (Swiss-Ped-IBrainD). Aims The Registry aims to describe epidemiology, demographics, diagnostics, management, and treatment, since these areas remain understudied in Switzerland. Additionally, we want to promote research by fostering the knowledge exchange between study centers and setting up studies such as national quality of life surveys. We further aim to facilitate the access to national and international studies for patients with a pediatric-onset inflammatory brain disease living and/or treated in Switzerland. Methods The Swiss-Ped-IBrainD is a multicentric, population-based, observational cohort study (IRB number: 2019-00377) collaborating with 11 neuropediatric centers in Switzerland. Patient screening, information and recruitment is mainly conducted by the local principal investigators. The data collection is organized centrally by the Executive Office of the registry. The collected data is purely observational. Medical records are the primary data source. All patients who have been diagnosed with a pediatric-onset inflammatory brain disease since 2005 are eligible. We aim to include all pediatric-onset inflammatory brain disease patients living and/or treated in Switzerland who meet the inclusion criteria. Considering existing literature and our single-center experience we anticipate 300-400 eligible patients.

- 43 Status
- 44 Currently, all 11 neuropediatric centers have been initiated and are recruiting. As of the first of May
- 45 2023, we have identified 275 eligible participants and obtained informed consent from 101 patients
- and/or families. None of the informed patients and/or families have refused participation.

Introduction

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

Pediatric-onset inflammatory brain diseases (IBrainDs) are rare central nervous system (CNS) diseases with the potential to cause life-threatening conditions. Often, patients experience an acute initial phase with neurological symptoms including focal neurological deficits, cognitive and/or behavioral dysfunctions, seizures, hemiparesis, and ataxia (1, 2). IBrainDs may be primary (idiopathic) or secondary in origin, e.g., as part of a systemic disease or infection (1-5). Irrespective of the origin, IBrainD pathology is characterized by immune cell activation, inflammation, cytokine, and/or antibody production. Specific inflammatory pathways target different structures in the CNS (2, 6). Such structures may be certain segments of blood vessels and neurons or CNS proteins such as myelin, cell surface receptors, channels, or enzymes (6). Based on either the affected structures or the disease mechanism, IBrainDs may be classified as demyelinating, antibodyassociated, T-cell mediated, granulomatous, or CNS vasculitis. Overall, pediatric-onset IBrainDs are rare. Incidences are only known for a few subgroups, such as demyelinating diseases 0.05-2.85/100'000 persons/year (7-14). Other IBrainDs are presumed to occur even less frequently. However, epidemiological data, particularly on children, are lacking. Rare diseases are inherently difficult to study. Their investigation requires special efforts and appropriate instruments. Patient registries are well suited to study the natural history of (rare) diseases; the Canadian pediatric demyelinating disease registry and BrainWorks – a Canadian registry for pediatric IBrainD patients – have markedly advanced the knowledge on IBrainDs in children (2, 6). Additionally, they have increased awareness and consecutively helped to improve the care of this vulnerable population.

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

Following their example, a national pediatric-onset IBrainD registry (Swiss-Ped-IBrainD) was founded in 2019. The primary focus of the Swiss-Ped-IBrainD is on the understudied areas in this field, such as epidemiology, health care management in general (and the diagnostic process in particular), as well as long-term patient outcomes. Epidemiological data such as prevalence, incidence, or prognostic data are invaluable for recognition of pediatric-onset IBrainDs by the healthcare system. This may favor future policymaking which addresses pediatric-onset IBrainDs. Pediatric-onset IBrainDs are often diagnosed with a significant delay, which entails a delay in treatment initiation. Optimizing the diagnostic process is one of our priorities since starting treatment early improves disease outcomes (3, 5, 6, 11) – particularly in demyelinating and antibody-mediated diseases. Researching the clinical phenotypes of pediatric-onset IBrainDs and gathering information on the diagnostic workup will help to differentiate the diseases and expedite the diagnosis. In an acute phase the treatment of IBrainDs is directed at controlling the inflammation. Following the acute intervention, many patients receive specific immunomodulatory treatment depending on the inflammatory pathways of the underlying IBrainD (6). Despite appropriate treatment, some children develop functional deficits (3, 11). We will assess these functional deficits and other outcomes of pediatric-onset IBrainD patients and hope to identify relevant factors that may be implemented in new treatment guidelines. Furthermore, the registry should enable patients with pediatric-onset IBrainDs to participate in international clinical studies for e.g., new drugs or new therapeutic regimens. Until now, these patients have rarely had the opportunity to participate in international studies – they were at a disadvantage compared to patients from countries with centralized registration such as France or Italy.

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

Through the Swiss-Ped-IBrainD registry and its linkage with other rare disease registries, we also expect to achieve high enough case numbers for statistically significant results. Materials and methods Main aims The Swiss-Ped-IBrainD registry has three main aims. Firstly, to provide detailed and comprehensive health reporting on pediatric-onset IBrainDs in Switzerland. The reporting includes but is not limited to the following areas of interest: epidemiology, demographics, diagnostics, management, and treatment. Secondly, to promote research by cultivating a regular exchange between the study centers and providing investigators with access to the high-quality structural data collected by the registry. Thirdly, to facilitate access to national and international studies for pediatric IBrainD patients living and/or treated in Switzerland. Procedure The Swiss-Ped-IBrainD Registry is a multicentric, population based, observational cohort study. The eleven neuropediatric centers in Switzerland shown in Figure 1 have agreed to participate. Figure 1: Participating Departments/Divisions of Neuropediatrcs, Child Neurology and Neuropsychology We expect to detect close to 100% of new pediatric-onset IBrainD patients. Since pediatric-onset IBrainDs are severe conditions requiring expert care, most patients in Switzerland will seek help at or be referred to one of the participating specialized centers. Child neurologists in private practices in Switzerland do not treat IBrainD patients themselves (15); missing new patients with a pediatric-onset IBrainD is therefore highly unlikely.

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

Patient screening is conducted by the principal investigators (PIs) of the study centers. They compile a screening list and inform all regularly seen, eligible patients of the registry. Patients who do not pay regular visits to the centers (due to various reasons including transition to adult care, moving, and treatment conclusion) may be informed by letter. All informed patients are invited to consent to study participation by means of signing the informed consent form. If the patient is underage, their parent(s)/guardian(s) must also sign the informed consent form. Recruitment has started on the 1st of November 2020. As is typical for a medical registry, recruitment is open-ended and therefore has no fixed end date. The signed consent form allows us to collect all of the patient's data (including identifying data) as defined in the case report forms. If patients or their families choose not to consent, we can still collect a de-identified minimal dataset including diagnosis, year of diagnosis, year of birth, sex, status (dead or alive) and cause of death, if applicable. This procedure has been approved by the local ethics committee to ensure the completeness of the epidemiological data. The collected data is purely observational. Medical records are the primary data source. The collection has retrospective and prospective components. Patient data from the time of diagnosis until present is collected and entered in the registry database (retrospective). Newly diagnosed pediatric IBrainD patients are recruited continuously. Their data as well as the follow-up data of formerly diagnosed patients are collected and updated regularly (prospective). The data collection itself is centrally organized by the Executive Office, which is the operational arm of Swiss-Ped-IBrainD and is located at the Institute of Social and Preventive Medicine (ISPM) at the University of Bern. The Executive Office is responsible for the collection of patient data from all participating centers (central data collection). The Executive Office and the PIs work together to maintain a continuous flow of data from the participating centers into the Swiss-Ped-IBrainD database.

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

Disease Family

This includes establishing access to source documents and case report forms for the Executive Office and the transformation of this into a standardized process. To promote joint research and advance patient management the Task Force on Patient Care and Management was founded. This working group meets bimonthly and is comprised of all PIs as well as additional experts in the field (neuropsychologists and neuroradiologists). The Swiss-Ped-IBrainD further provides the basis for national surveys, since questionnaire studies in line with the objectives of the Swiss-Ped-IBrainD are covered by the ethical approval. We are currently preparing the first questionnaire on patient/family perceptions of the diagnostic process and quality of life. Study Population Regarding the target population, we aim to include all pediatric-onset IBrainD patients living or treated in Switzerland who have been diagnosed since 2005 (Swiss population ≤ 33 years of age: 3'260'287 (Statistik 2010)). Because epidemiological data on pediatric-onset IBrainDs is scarce, the number of eligible patients is merely a rough estimate. Incidences between 0.05-2.85/100'000 persons/year (7-14) have been reported for demyelinating diseases of the CNS and 0.04-0.33/100'000 persons/year (16, 17) for other IBrainDs such as pediatric-onset anti-NMDA receptor encephalitis. Considering these numbers and our single center experience we anticipate 300-400 eligible patients. Inclusion criteria Patients living and/or treated in Switzerland diagnosed since 2005 with one of the pediatric-onset IBrainDs listed in Table 1. Table 1: Pediatric-onset inflammatory brain diseases to be included in the Swiss Pediatric Inflammatory Brain Disease Registry. The list of the included diagnoses might evolve over time given the active research in the field and validation of new techniques for diaanosis.

Diagnosis

Demyelinating	Optic neuritis
	Transverse myelitis
	Acute disseminated encephalomyelitis
	Multiple sclerosis
	Neuromyelitis optica spectrum disorders
Antibody associated	Anti-NMDA-R
	Anti-GAD65
	Anti-AMPA-1/2
	Anti-Lgi-1
	Anti-CASPR-2
	Anti-GABA-1/2
	Onconeuronal antibodies
	Hashimoto encephalopathy
T-cell mediated	Rasmussen's encephalitis
Other	CNS Vasculitis
	CNS Sarcoidosis
	CNS Lupus

Exclusion criteria

158

159

160

161

162

163

164

165

166

167

168

169

170

171

Patients with neurological symptoms due to infectious diseases of the CNS or congenital infections (such as TORCH, peripheral facial palsy), patients with genetic metabolic causes of central demyelinating diseases and patients with neurological symptoms due to Guillain-Barré-Syndrome will be excluded from participation.

Organization

Swiss-Ped-IBrainD has two main bodies: the Steering Board and the Executive Office.

The Steering Board consists of medical specialists, mainly pediatric neurologists, and has an elected

President and Vice-President. It supervises the Executive Office and sets the direction.

The Executive Office, located at the ISPM, consists of the Co-Heads (Swiss-Ped-IBrainD Legal

Representative and Clinical Lead), the Project Manager, the Data Manager and other team members. It

manages the database, the variables, the archived documents, and the information on organization

rules.

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

Other closely linked structures are the participating clinics and the Task Force on Patient Care and Management. The main task of the participating clinics is to recruit patients and provide data to the Swiss-Ped-IBrainD. The main task of the Task Force is to discuss complex cases, establish standards of care and work on pressing issues in the field of pediatric-onset IBrainDs. Figure 1 shows the organization of the Swiss-Ped-IBrainD and its associated structures. Figure 2: Organizational structure of the Swiss Pediatric Inflammatory Brain Disease Registry; PM: Project management; DM: Data management Ethics statement This project was approved by the cantonal ethics committee of Bern (IRB number: 2019-00377) as well as the ethics committees of Northwest and Central Switzerland, Ticino, Zürich, Geneva, Vaud, and East Switzerland, which cover the 11 study centers. It is and will be conducted in accordance with the protocol, the Declaration of Helsinki (18), the principles of Good Clinical Practice (19), the Human Research Act (20) and the Human Research Ordinance (21) as well as other locally relevant regulations. The Swiss-Ped-IBrainD will further adhere to the recent recommendations for health-related registries elaborated by the National Association for Quality Development in Hospitals and Clinics, Swiss Medical Association, Swiss Hospitals Association, Swiss Academy of Medical Sciences, and University Medicine Switzerland (22). These recommendations serve as basis for quality assurance of registries. Data management We collect and archive all personal, medical, and questionnaire data as well as digitalized documents of the project in a dedicated electronic data capturing system (REDCap ISPM UniBe). The database complies with all requirements for data security and protection.

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

Statistical analysis plan Since the registry has no designated endpoint, we will continuously analyze the collected data and update results according to our evolving objectives. Initially, descriptive statistics (mean and standard deviation, median and range, summary tables and simple graphics) will serve to characterize pediatric-onset IBrainD patient population of Switzerland. Subsequently, we plan to investigate between-group differences with tests such as t-tests, chi-squared, Wilcoxon-Mann, and Fisher's exact depending on the variables in question. For more advanced analyses including associations between factors, we will use regression modelling (logistic, linear, Poisson). For follow-up data we will apply statistical methods appropriate for longitudinal data such as cox and Poisson regression or Kaplan-Meier survival curves. We also intend to supplement our datasets with data from relevant routine data and other registries. This allows conducting case-control studies or cohort-based studies about causes and the long-term course of pediatric-onset IBrainDs. For all analyses we will use STATA (STATA Corp LP, Texas USA) and R (R Foundation for Statistical Computing, Vienna, Austria) or comparable statistical software. Safety considerations The project participation entails minimal risks and burdens (category A). We do not expect any safety issues and therefore refrain from implementing protective measures. Current status Currently, all 11 neuropediatric centers have been initiated and are recruiting. As of the first of May 2023, we have identified 275 eligible participants and obtained 101 informed consents from patients and/or families. None of the informed patients and/or families have refused participation.

Results of this project will be published in scientific journals and presented at scientific conferences.

Authorship will be handled according to the ICMJE (www.icmje.org). Ongoing studies and short summaries of the latest news are published on the project website. We will generate annual reports of the Swiss-Ped-IBrainD.

Discussion

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

Potential problems and limitations We want to reach completeness – meaning we want to collect data from the entire target population. This is challenging since some patients, especially those with mild IBrainDs, may no longer require continued medical care. They are therefore difficult to find and reach (selection/recruitment bias). However, we will exploit all available and legal measures to recruit as many patients as possible. To directly address and minimize the effect of selection/recruitment bias we will collect the minimal dataset from all identified patients after they have been informed. Misclassification may be a further limitation. To reduce misclassification, we rely on an international classification system and results from biopsies, electrophysiological examinations, and specific laboratory testing (e.g., presence of disease-identifying antibodies such as NMDA-R-AB or NMO-lgG). Patients without a precise diagnosis will not be included. We will also run regular plausibility checks. Missing data is a further limitation we foresee. To minimize data gaps in the medical history of the patients, we have centralized the data collection; a member of the Executive Office regularly visits the participating centers and collects patient data. These data-collection visits are also good opportunities to resolve open queries and monitor recruitment. Regarding data from questionnaires, we will remind patients to return their questionnaires. On the analysis level, we will use inverse probability weighting to account for an eventual attrition bias (23). This procedure gives more weight to well-explained observations (by baseline data) and thereby compensates for non-observed follow-up data. Missing data may also be computed by multiple imputation, as done in previous studies (24).

Amendments and end of project

Substantial changes to the project set-up, the protocol and relevant project documents will be submitted to the responsible institutional review board for approval. This includes the distribution of questionnaires to patients and families.

The project has no defined endpoint. However, the Swiss-Ped-IBrainD may be terminated or suspended due to financial or personnel-related reasons.

Acknowledgements

247

248 We thank Lilianna Bolliger for important ground-laying work.

References

- 250 1. Cellucci T, Tyrrell PN, Twilt M, Soon GS, Yau I, Sheikh S, et al. Distinguishing features in the
- 251 presentations of childhood inflammatory brain diseases at a tertiary-care centre. Pediatric
- 252 Rheumatology Online Journal. 2012;10(Suppl 1):A81.
- 253 2. Liu E, Twilt M, Tyrrell PN, Dropol A, Sheikh S, Gorman M, et al. Health-related quality of life in
- 254 children with inflammatory brain disease. Pediatric Rheumatology Online Journal. 2018;16(1):73.
- 255 3. Smitka M, Bruck N, Engellandt K, Hahn G, Knoefler R, von der Hagen M. Clinical Perspective on
- 256 Primary Angiitis of the Central Nervous System in Childhood (cPACNS). Frontiers in pediatrics.
- 257 2020;8:281.

- 258 4. Twilt M, Sheikh S, Benseler S. PReS-FINAL-2362: The spectrum of childhood inflammatory brain
- 259 diseases; an increasingly recognised field. Pediatric Rheumatology Online Journal. 2013;11(Suppl
- 260 2):P352.
- 5. Twilt M, Benseler SM. CNS vasculitis in children. Multiple sclerosis and related disorders.
- 262 2013;2(3):162-71.
- 263 6. Twilt M, Benseler SM. Childhood inflammatory brain diseases: pathogenesis, diagnosis and
- 264 therapy. Rheumatology (Oxford, England). 2014;53(8):1359-68.
- 265 7. Metz I, Weigand SD, Popescu BF, Frischer JM, Parisi JE, Guo Y, et al. Pathologic heterogeneity
- persists in early active multiple sclerosis lesions. Annals of neurology. 2014;75(5):728-38.
- 267 8. Pavone P, Pettoello-Mantovano M, Le Pira A, Giardino I, Pulvirenti A, Giugno R, et al. Acute
- 268 disseminated encephalomyelitis: a long-term prospective study and meta-analysis. Neuropediatrics.
- 269 2010;41(6):246-55.
- 270 9. Langer-Gould A, Zhang JL, Chung J, Yeung Y, Waubant E, Yao J. Incidence of acquired CNS
- demyelinating syndromes in a multiethnic cohort of children. Neurology. 2011;77(12):1143-8.
- 272 10. Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF, Boon M, van Dijk KG, Eikelenboom MJ,
- et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study.
- 274 Journal of neurology. 2012;259(9):1929-35.
- 275 11. Bigi S, Hladio M, Twilt M, Dalmau J, Benseler SM. The growing spectrum of antibody-associated
- inflammatory brain diseases in children. Neurology(R) neuroimmunology & neuroinflammation.
- 277 2015;2(3):e92.
- 278 12. Burton KLO, Williams TA, Catchpoole SE, Brunsdon RK. Long-Term Neuropsychological Outcomes
- 279 of Childhood Onset Acute Disseminated Encephalomyelitis (ADEM): a Meta-Analysis. Neuropsychology
- 280 review. 2017;27(2):124-33.
- 281 13. Jeong A, Oleske DM, Holman J. Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic
- Review of the Literature. Journal of child neurology. 2019;34(12):705-12.
- 283 14. Yan K, Balijepalli C, Desai K, Gullapalli L, Druyts E. Epidemiology of pediatric multiple sclerosis: A
- 284 systematic literature review and meta-analysis. Multiple sclerosis and related disorders.
- 285 2020;44:102260.
- 286 15. Hofer S, Bauder F, Capone Mori A, Chan A, Dill P, Garcia-Tarodo S, et al. Management of Acute
- 287 Demyelinating Attacks in the Pediatric Population: A Swiss Consensus Statement. Clinical and
- 288 Translational Neuroscience. 2021;5(2):17.
- 289 16. Giri YR, Parrill A, Damodar S, Fogel J, Ayed N, Syed M, et al. Anti-N-Methyl-D-Aspartate Receptor
- 290 (NMDAR) Encephalitis in Children and Adolescents: A Systematic Review and Quantitative Analysis of
- 291 Reported Cases. Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de
- l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent. 2021;30(4):236-48.

- 293 17. Ho AC, Chan SH, Chan E, Wong SS, Fung ST, Cherk SW, et al. Anti-N-methyl-d-aspartate receptor
- encephalitis in children: Incidence and experience in Hong Kong. Brain & development. 2018;40(6):473-
- 295 9.

- 296 18. Association WM. World Medical Association Declaration of Helsinki: ethical principles for
- medical research involving human subjects. Jama. 2013;310(20):2191-4.
- 298 19. (ICH) ICfhotrfpfhu. Integrated addendum to ICH E6(R1): GUIDELINE FOR GOOD CLINICAL
- 299 PRACTICE E6(R2). 2016.
- 300 20. (KAV) SB. Bundesgesetz über die Forschung am Menschen (Humanforschungsgesetz, HFG;
- 301 Human Research Act. 2013.
- 302 21. (KAV) SB. Verordnung über die Humanforschung mit Ausnahme der klinischen Versuche
- 303 (Humanforschungsverordnung, HFV): Human Research Ordinance. In: Gesundheit Bf, editor. 2013.
- 304 22. Busch P, Heller R, Hofstetter A, Clerc V, Kern A, Nienhaus A, et al. Recommendations for the
- development and operation of health-related registries. 2.0 ed2019.
- 306 23. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding
- in Observational Studies. Multivariate behavioral research. 2011;46(3):399-424.
- 308 24. Dogaru CM, Strippoli MP, Spycher BD, Frey U, Beardsmore CS, Silverman M, et al. Breastfeeding
- and lung function at school age: does maternal asthma modify the effect? American journal of
- respiratory and critical care medicine. 2012;185(8):874-80.




Figure 1




Figure 2